Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 4.01 Million | 3.91 Million | 5.12 Million | 4.33 Million | - | 108.53 Thousand |
| Cost of Revenue | 214.3 Thousand | 102.26 Thousand | 54.21 Thousand | 75.36 Thousand | 112.42 Thousand | 29.69 Thousand |
| Gross Profit | 3.8 Million | 3.81 Million | 5.06 Million | 4.26 Million | -112.42 Thousand | 78.84 Thousand |
| Operating Expenses | 23.4 Million | 18.42 Million | 15.13 Million | 14.73 Million | 10.06 Million | 12.47 Million |
| Selling, General and Administrative Expenses | 4.76 Million | 5.22 Million | 5.45 Million | 6.86 Million | 3.33 Million | 4.27 Million |
| Research and Development Expenses | 18.64 Million | 13.19 Million | 14.74 Million | 12.28 Million | 10.09 Million | 12.98 Million |
| Other Expenses | - | - | -364.66 Thousand | -360.02 Thousand | -352.92 Thousand | -322.09 Thousand |
| Cost and Expenses | 23.62 Million | 18.52 Million | 15.13 Million | 14.73 Million | 10.06 Million | 12.47 Million |
| Operating Income | -19.6 Million | -18.52 Million | -17.85 Million | -14.5 Million | -10.41 Million | -12.71 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 46.08 Thousand | -3.8 Million | 70 Thousand | 210.63 Thousand | -362.18 Thousand | -349.06 Thousand |
| Earnings before Tax | -19.07 Million | -17.61 Million | -12.77 Million | -15.3 Million | -10.05 Million | -12.33 Million |
| Net Income | -19.12 Million | -13.8 Million | -12.84 Million | -15.3 Million | -10.05 Million | -12.33 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Weighted Average Shares Outstanding | 3.64 Billion | 2.42 Billion | 2.4 Billion | 1.69 Billion | 894.87 Million | 615.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.64 Billion | 2.42 Billion | 2.4 Billion | 1.69 Billion | 894.87 Million | 615.77 Million |
| Gross Margin | 0.95 | 0.97 | 0.99 | 0.98 | - | 0.73 |
| EBIT Margin | -4.87 | -4.70 | -3.48 | -3.33 | - | -116.86 |
| Profit Margin | -4.76 | -3.53 | -2.51 | -3.53 | - | -113.67 |
| EBITDA | -19.57 Million | -14.59 Million | -15.48 Million | -15.15 Million | -13.9 Million | -12.76 Million |
| Earnings Before Tax Margin | -4.88 | -4.73 | -3.49 | -3.34 | - | -117.14 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | - | 1.05 Million | 1.05 Million | 950.36 Thousand | 950.36 Thousand | 3.91 Million |
| Cost of Revenue | 147.52 Thousand | 73.61 Thousand | 58.66 Thousand | 73.91 Thousand | 48.48 Thousand | 102.26 Thousand |
| Gross Profit | -147.52 Thousand | 985.66 Thousand | 1 Million | 876.44 Thousand | 901.87 Thousand | 3.81 Million |
| Operating Expenses | 23.47 Million | 15.02 Million | 7.49 Million | 8.44 Million | 4.21 Million | 18.42 Million |
| Selling, General and Administrative Expenses | - | 2.74 Million | 1.35 Million | 2.08 Million | 1.03 Million | - |
| Research and Development Expenses | - | 12.28 Million | 6.14 Million | 6.36 Million | 3.18 Million | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 23.62 Million | 15.1 Million | 7.55 Million | 8.51 Million | 4.26 Million | 18.52 Million |
| Operating Income | -23.62 Million | -15.1 Million | -6.49 Million | -8.51 Million | -3.31 Million | -18.52 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -3.97 Million | -2.07 Million | 23.04 Thousand | -1.9 Million | - | -3.8 Million |
| Earnings before Tax | -23.09 Million | -14.68 Million | -6.28 Million | -8.4 Million | -3.25 Million | -17.61 Million |
| Net Income | -19.12 Million | -12.61 Million | -6.3 Million | -6.5 Million | -3.25 Million | -13.8 Million |
| Earnings Per Share Basic | - | -0.00 | -0.00 | -0.00 | -0.00 | - |
| Earnings Per Share Diluted | - | -0.00 | -0.00 | -0.00 | -0.00 | - |
| Weighted Average Shares Outstanding | 5.24 Billion | 3.07 Billion | 3.07 Billion | 2.5 Billion | 2.5 Billion | 2.42 Billion |
| Weighted Average Shares Outstanding (Diluted) | 5.24 Billion | 3.07 Billion | 3.07 Billion | 2.5 Billion | 2.5 Billion | 2.42 Billion |
| Gross Margin | - | 0.93 | 0.94 | 0.92 | 0.95 | 0.97 |
| EBIT Margin | - | -14.19 | -6.12 | -8.89 | -3.47 | - |
| Profit Margin | - | -11.91 | -5.96 | -6.85 | -3.42 | -3.53 |
| EBITDA | - | -15.02 Million | -6.48 Million | -8.44 Million | -3.3 Million | - |
| Earnings Before Tax Margin | - | -14.26 | -6.13 | -8.96 | -3.48 | -4.73 |
CITE
UNMA
63MOONS
GPDB
IPL
EMCHF